AI Article Synopsis

  • Pancreatic adenocarcinoma (PAAD) has a low survival rate, prompting the development of a zinc finger (ZNF) protein-based prognostic prediction model.
  • The model utilized RNA-seq data from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) to identify differentially expressed ZNF genes (DE-ZNFs) and established a risk score with 10 key DE-ZNFs that can independently predict patient outcomes.
  • The study also created a ceRNA regulatory network linking these genes with various miRNAs and lncRNAs, finding significant expression differences in several ZNFs between high- and low-risk PAAD patients, ultimately aiming to enhance patient management strategies.

Article Abstract

Pancreatic adenocarcinoma (PAAD) is among the most devastating of all cancers with a poor survival rate. Therefore, we established a zinc finger (ZNF) protein-based prognostic prediction model for PAAD patients. The RNA-seq data for PAAD were downloaded from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) databases. Differentially expressed ZNF protein genes (DE-ZNFs) in PAAD and normal control tissues were screened using the "lemma" package in R. An optimal risk model and an independent prognostic value were established by univariate and multivariate Cox regression analyses. Survival analyses were performed to assess the prognostic ability of the model. We constructed a ZNF family genes-related risk score model that is based on the 10 DE-ZNFs (ZNF185, PRKCI, RTP4, SERTAD2, DEF8, ZMAT1, SP110, U2AF1L4, CXXC1, and RMND5B). The risk score was found to be a significant independent prognostic factor for PAAD patients. Seven significantly differentially expressed immune cells were identified between the high- and low-risk patients. Then, based on the prognostic genes, we constructed a ceRNA regulatory network that includes 5 prognostic genes, 7 miRNAs and 35 lncRNAs. Expression analysis showed ZNF185, PRKCI and RTP4 were significantly upregulated, while ZMAT1 and CXXC1 were significantly downregulated in the PAAD samples in all TCGA - PAAD, GSE28735 and GSE15471 datasets. Moreover, the upregulation of RTP4, SERTAD2, and SP110 were verified by the cell experiments. We established and validated a novel, Zinc finger protein family - related prognostic risk model for patients with PAAD, that has the potential to inform patient management.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10311482PMC
http://dx.doi.org/10.3389/fgene.2023.1089023DOI Listing

Publication Analysis

Top Keywords

paad
8
zinc finger
8
paad patients
8
differentially expressed
8
risk model
8
independent prognostic
8
risk score
8
znf185 prkci
8
prkci rtp4
8
rtp4 sertad2
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!